CN100363000C - Chinese and western medicines composition contg. Avandia and its prepn. method - Google Patents

Chinese and western medicines composition contg. Avandia and its prepn. method Download PDF

Info

Publication number
CN100363000C
CN100363000C CNB2006101279116A CN200610127911A CN100363000C CN 100363000 C CN100363000 C CN 100363000C CN B2006101279116 A CNB2006101279116 A CN B2006101279116A CN 200610127911 A CN200610127911 A CN 200610127911A CN 100363000 C CN100363000 C CN 100363000C
Authority
CN
China
Prior art keywords
parts
chinese
diabetes
compositions
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2006101279116A
Other languages
Chinese (zh)
Other versions
CN1911348A (en
Inventor
胡可丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2006101279116A priority Critical patent/CN100363000C/en
Publication of CN1911348A publication Critical patent/CN1911348A/en
Application granted granted Critical
Publication of CN100363000C publication Critical patent/CN100363000C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

A synergistic medicine containing rogridone and the extracts of Chinese-medicinal materials and its application in preparing the medicines for treating diabetes are disclosed.

Description

Contain Chinese and western medicinal composition of rosiglitazone and preparation method thereof
Technical field
The present invention relates to a kind of Chinese and western medicinal composition for the treatment of diabetes, specifically contain the compositions of rosiglitazone and Chinese medicine extract, and the purposes of said composition in preparation treatment type ii diabetes medicine.
Background technology
Diabetes are a kind of complex diseases because of syndrome, be since in the body hormone of insulin deficit or antagonism insulin increase, or insulin can not be brought into normal play physiological action and a kind of syndrome of the glucose, protein and the lipid metabolic disorder that cause in target cell.It is characterized by the unusual rising of concentration of glucose and glucose in urine in the blood circulation, occur typical " three-many-one-little " symptom when blood glucose is too high, promptly eat, polyuria, polyphagia and lose weight more, and with fatigue and weak.Ketoacidosis, hypertonicity diabetic coma can take place in severe patient, and easily merge multiple infection.Along with the prolongation of the course of disease, its metabolism disorder can cause the chronic pathological changes of histoorgans such as eye, kidney, nerve, blood vessel and heart.If can not get timely, appropriate treatment, heart change, cerebrovascular disease, renal failure then take place, lose the sight of both eyes, situation such as lower limbs necrosis, become disable, lethal main cause.And onset diabetes rate height, the national sampling survey of 1995-1996, natural crowd's prevalence is up to 3.21% more than 20 years old, the whole nation 300,000 census of the population results in 1980, prevalence 4.21% more than 60 years old, single Jiangsu elderly population diabetes, impaired glucose tolerance prevalence then are respectively 14.49% and 10.21%, and no matter are developed country or developing country, and the sickness rate of diabetes is all rising year by year.
Mostly the medicine of clinical treatment 2 types is chemicals, widely used sulphanylureas, biguanides, other antidiabetic drugs and the adjuvant drug of being broadly divided into except that insulin at present.The sulfonylureas drugs for diabetes thing is topmost Remedies for diabetes.Can make that hepatic glycogen is synthetic to be increased,, surrounding tissue be strengthened to the sensitivity of insulin, the picked-up of glucose is increased, thereby reach the effect of blood sugar lowering again by the effect behind pair cell receptor or the receptor.But more easily cause untoward reaction such as hypoglycemia, granulocytopenia and cardiovascular disease.Biguanides antidiabetic drug heavy dose can cause digestive tract should, have the patient of pathological changes easily to cause lactic acidosis at lung, liver, kidney.Bring hidden danger for the extensive patients drug safety, for a change this situation for a long time, attempts treating with protocol in the plant clinically always.The traditional Chinese medical science is consistent to the cause of disease view of diabetes, thinks it mainly is that surfeit delicious food, overaction of the five emotions, chamber do not save, the dry and not enough Several Factors of natural endowment of calentura fire.But Chinese medicine also comes with some shortcomings, and is slow as onset, need having the experience old docter of TCM to identify and correct use etc. under instructing.The present invention attempts Chinese medicine and Western medicine are combined, and with the problem of avoiding existing separately, and improves the treatment of diabetes effect, promptly produces synergism.
Summary of the invention
One object of the present invention is to provide the Pharmaceutical composition of being made up of rosiglitazone and a kind of Chinese medicine extract, wherein prepares on the prescription basis of the Chinese medicine extract of said composition according to Chinese patent CN1232291C embodiment 1, and is as follows:
With 10 parts of Cortex Acanthopanciss, 5 parts of Rhizoma Polygoni Cuspidati, 10 parts of Radix campsis, 10 parts of Rhizoma Dioscoreaes, 10 parts of Herba Agrimoniaes, 8 parts on Folium Mori, decoct with water by weight, filter, be concentrated into thick paste, drying.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in the medicine of preparation treatment diabetes.
This Chinese medical concrete is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has strong antidiabetic effect, i.e. hypoglycemic activity.
Edit with reference to Zhang Juntian, " modern pharmacology test method " (first volume), combined publication society of China Concord Medical Science University of Beijing Medical University, the 984-985 page or leaf, disclosed method in " animal model of the similar type ii diabetes of second joint ", set up experimental obesity and diabetes rat model, carry out the hypoglycemic pharmacodynamics test of Pharmaceutical composition of the present invention.
The test grouping:
1 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: the water extracted immersing paste 1.02g/kg body weight as indicated above
3 rosiglitazone groups: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight rosiglitazone+extractum 1.02g/kg body weight mentioned above is irritated stomach.
Group Blood glucose mmol/l
0 day 7 weeks
Group 1 5.2±1.7 5.2±1.3
Group 2 4.9±1.1 4.0±2.5
Group 3 5.3±1.4 4.1±1.8
Group 4 5.5±1.1 3.9±0.9
This table shows that all there is significant difference (P<0.05) in each group (pure Chinese drug-treated group, rosiglitazone group, compositions group) of treatment with model control group, and all there are significant difference (P<0.05) in compositions group and pure Chinese drug-treated group, compositions group and rosiglitazone group.Show that there are cooperative effect in rosiglitazone and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio rosiglitazone and described Chinese medicine extract at 1: 102.Can produce the capsule that contains following component in a conventional manner:
Component The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Pulvis Talci 5.0
Wherein compositions is made up of with weight ratio rosiglitazone and described Chinese medicine extract at 1: 102.

Claims (2)

1. a compositions for the treatment of diabetes is characterized in that being made up of at 1: 102 with weight ratio rosiglitazone and Chinese medicine extract, and wherein this Chinese medicine extract is made according to following method:
With 10 parts of Cortex Acanthopanciss, 5 parts of Rhizoma Polygoni Cuspidati, 10 parts of Radix campsis, 10 parts of Rhizoma Dioscoreaes, 10 parts of Herba Agrimoniaes, 8 parts on Folium Mori, decoct with water by weight, filter, be concentrated into thick paste, drying.
2. the purposes of compositions as claimed in claim 1 in the medicine of preparation treatment diabetes.
CNB2006101279116A 2006-09-01 2006-09-01 Chinese and western medicines composition contg. Avandia and its prepn. method Expired - Fee Related CN100363000C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006101279116A CN100363000C (en) 2006-09-01 2006-09-01 Chinese and western medicines composition contg. Avandia and its prepn. method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006101279116A CN100363000C (en) 2006-09-01 2006-09-01 Chinese and western medicines composition contg. Avandia and its prepn. method

Publications (2)

Publication Number Publication Date
CN1911348A CN1911348A (en) 2007-02-14
CN100363000C true CN100363000C (en) 2008-01-23

Family

ID=37720512

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006101279116A Expired - Fee Related CN100363000C (en) 2006-09-01 2006-09-01 Chinese and western medicines composition contg. Avandia and its prepn. method

Country Status (1)

Country Link
CN (1) CN100363000C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105709100A (en) * 2016-03-27 2016-06-29 济南邦文医药科技有限公司 Medicine composition for treating diabetes containing rosiglitazone and preparation method of medicine composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1277965A (en) * 2000-06-14 2000-12-27 中国医药研究开发中心 Luogelie ketone hydrochloride and its use
CN1555865A (en) * 2004-01-12 2004-12-22 季长春 Medicine for treating diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1277965A (en) * 2000-06-14 2000-12-27 中国医药研究开发中心 Luogelie ketone hydrochloride and its use
CN1555865A (en) * 2004-01-12 2004-12-22 季长春 Medicine for treating diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
丹蛭降糖胶囊对胰岛素抵抗大鼠PPAR-γ mRNA表达的丹蛭降糖胶囊对胰岛素抵抗大鼠PPAR-γ mRNA表达的影响. 方朝晖,王佑民,王开成,郭彦,刘玲,胡国平.中国实验方剂学杂志,第12卷第4期. 2006 *
罗格列酮联合中药治疗肥胖性2型糖尿病临床观察. 吕蕾,刘照峰,尹翠梅.中西医结合心脑血管病杂志,第1卷第7期. 2003 *

Also Published As

Publication number Publication date
CN1911348A (en) 2007-02-14

Similar Documents

Publication Publication Date Title
CN102526479A (en) Health-care medicine formula with functions of enhancing immunity and lowering blood sugar
CN103405655A (en) Traditional Chinese medicine composition for reducing blood glucose and preparation method thereof
CN103417846B (en) Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof
CN101264203B (en) Chinese and western medicine composition for treating diabetes
CN102861201A (en) Medicine composition for treating diabetes and preparation method thereof
CN100363000C (en) Chinese and western medicines composition contg. Avandia and its prepn. method
CN106176773A (en) Berberine hydrochloride and stachyose composition compositions and application
CN104644734A (en) Drug for treating type II diabetes and complications thereof
CN101829271B (en) Chinese medicinal compound with function of treating diabetes and preparation method and application thereof
CN101406642B (en) Antihypelipidemic compound formulation
CN104906145B (en) Medical application of the Paecilomyces hepiali chen mutagenic strain PH40 in treatment diabetes
CN100362988C (en) Chinese and western medicine composition contg. metformin
CN100362998C (en) Medicine composition for treating diabetes
CN100381150C (en) Composition comprising epalrestat
CN113648380A (en) Composition for treating diabetes
CN101791350B (en) Glibenclamide-containing traditional Chinese and western medicine composition
CN101757253B (en) Traditional Chinese medicine and Western medicine composition containing gliquidone
CN101406576B (en) Chinese medicine for treating diabetes and preparation method
CN101773572B (en) Chinese-western medicine composition containing nateglinide
CN101791351B (en) Glipizide-containing traditional Chinese and western medicine composition
CN102198174B (en) Traditional Chinese medicine formulated preparation for nourishing kidney, removing heat from liver, reducing sugar and regulating fat, and preparation method thereof
CN101347511B (en) Medicament composition with function for reducing blood sugar
CN105168203A (en) Application of schisandrin B in preparation of diabetes treatment drug
CN101537102A (en) Medical and edible dual-purpose composition for treating sugar diabetes and preparation method thereof
CN101791352B (en) Phenformin-containing traditional Chinese and western medicine composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Chen Tong

Document name: Written notice of preliminary examination of application for patent for invention

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Chen Tong

Document name: Notice of application for publication of patent for invention and entry into the substantive examination procedure

C14 Grant of patent or utility model
C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Yang Xue

Document name: Notification of Passing Examination on Formalities

GR01 Patent grant
C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Yang Xue

Document name: Notification to Pay the Fees

C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Yang Xue

Document name: Notification of Termination of Patent Right

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee